[Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) CAS NO.255710-51-1

[Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) is a synthetic peptide analog derived from the PMEL17/gp100 melanocyte differentiation antigen, featuring specific amino acid deletions at positions 186 and 187 to enhance stability and immunogenicity. This research-grade peptide represents a modified version of the native HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitope, designed for improved presentation and recognition in immunological studies. The product is provided as a lyophilized powder with high purity and is intended for preclinical research applications in tumor immunology, melanoma research, and T cell immunology, serving as a valuable tool for investigating antigen-specific immune responses and T cell activation mechanisms in both academic and pharmaceutical research settings.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	[Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)
CAS NO.	255710-51-1
Appearance	White to off-white lyophilized powder
Molecular Formula	C43H69N9O11S
Molecular Weight	920.15g/mol
Purity (RP-HPLC)	≥ 95.0%
Solubility	Soluble in water, physiological saline, or PBS buffer. It is recommended to prepare a stock solution of 1–10 mg/mL using sterile water or PBS, aliquot, and store at ≤-20°C.
Endotoxin	< 1.0 EU/mg
Biological Activity	This product is an immunodominant CTL epitope modified from the PMEL17/gp100 protein, which can be used for T cell immune recognition studies and tumor immunology-related experiments. Its activity needs to be verified through in vitro T cell stimulation experiments.
Storage Conditions	Lyophilized powder: Store at -20°C or lower in a dry environment protected from light; it is stable for a long time. Reconstituted solution: After aliquoting, store frozen at ≤-20°C, avoiding repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

The mechanism of action involves presentation of this modified peptide epitope by major histocompatibility complex (MHC) class I molecules, particularly HLA-A*0201, on the surface of antigen-presenting cells. When presented, the peptide is recognized by specific T cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, leading to T cell activation, proliferation, and the generation of antigen-specific immune responses. The specific amino acid deletions (Des-Asp187, Met186) in this analog are designed to enhance peptide stability, improve MHC binding affinity, and potentially increase immunogenicity compared to the native epitope, thereby facilitating more robust T cell activation in experimental systems for studying antigen-specific immune recognition and T cell-mediated cytotoxicity.

2.PRODUCT INDICATIONS

This PMEL17/gp100 peptide analog is indicated for research use only in preclinical studies investigating tumor immunology, melanoma antigen recognition, T cell activation mechanisms, and cancer immunotherapy development. It serves as a specific antigenic peptide for in vitro T cell stimulation assays, ELISPOT assays, intracellular cytokine staining, and the generation of antigen-specific T cell lines or clones. The product is also used in studies of antigen presentation, MHC-peptide binding assays, and the evaluation of T cell receptor recognition in the context of melanoma and other cancers expressing PMEL17/gp100. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals, and should be handled by trained research personnel in appropriate laboratory settings.

3.CLINICAL EFFICACY OF PRODUCT

As a research reagent, [Des-Asp187,Met186]-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) does not have established clinical efficacy for therapeutic use in human patients. While this peptide analog and related PMEL17/gp100 epitopes have been studied in preclinical models and some early-phase clinical trials of cancer vaccines and adoptive T cell therapies, the product itself has not undergone clinical development or received regulatory approval for any medical indication. Research using this peptide has contributed to the understanding of tumor antigen recognition and the development of immunotherapeutic strategies, but the product remains an investigational research tool without proven clinical efficacy or safety profile for human use.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.